A new study from the Blue Cross Blue Shield Association (BCBSA) is raising red flags about how AI tools are reshaping healthcare billing. Between 2024 and 2025, providers increasingly documented secondary conditions — illnesses coexisting alongside the primary diagnosis — driving up costs by $653 million for BCBS companies. In total, more intensive care documentation added $942 million in costs over the two-year period compared to 2023.

The culprit? AI tools like ambient scribes and record-scanning software that passively identify additional billable conditions from patient records and conversations. More complex documented cases mean higher reimbursements — especially in hospital settings where secondary conditions can bump a case into a higher-cost category.

But here's the catch: the data doesn't show a corresponding rise in actual treatment. For example, diagnoses of anemia increased, but blood transfusions — a standard treatment — did not. Similarly, secondary conditions flagged during major bowel surgeries surged, without matching upticks in care.

By the Numbers:

• $942M in additional costs to BCBS firms over two years (2024–2025 vs. 2023)
• $653M driven specifically by increased secondary condition billing
• 55% increase in partial intestinal blockage diagnoses during bowel surgeries
• 33% increase in acid overload diagnoses during bowel surgeries
• 100M+ people covered by BCBSA's 31 member insurers

Why it matters: If AI is inflating billing without improving patient care, it signals a systemic problem at the intersection of technology, reimbursement, and accountability — one that could reshape how insurers scrutinize AI-assisted documentation going forward.